~~<i id='93D1F5147D'><strike id='93D1F5147D'><tt id='93D1F5147D'><pre id='93D1F5147D'></pre></tt></strike></i>~~

Home» leisure time» Wikipedia

Wikipedia

author：entertainment 2025-10-04 10:13:24 Page View：471

For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.

Editas Medicine, the winner of that battle in the U.S., will now cash in.

Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes
Next article： What does generative AI mean for health care? We asked experts

explore

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

Eye stem cell transplant could help restore vision in injured people

UlaJurkunas,associatedirectorofthecorneaserviceatMassEyeandEar,performsthefirstCALECsurgery.Courtesy

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

Florida officials tell state schools to teach AP Psychology 'in its entirety'

1:29.STOCKIMAGE/GettyImagesFloridaEducationCommissionerMannyDiaz,Jr.hasinstructedFloridaschooloffici